Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.6302
+0.02293.77%
Post-market: 0.63020.00000.00%16:10 EDT
Volume:519.11K
Turnover:324.75K
Market Cap:24.89M
PE:-0.33
High:0.6433
Open:0.6004
Low:0.6004
Close:0.6073
52wk High:5.14
52wk Low:0.4300
Shares:39.50M
Float Shares:30.75M
Volume Ratio:1.14
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9003
EPS(LYR):-1.6652
ROE:-101.55%
ROA:-55.53%
PB:0.49
PE(LYR):-0.38

Loading ...

High-Risk Warning: Analyst Flags Significant Uncertainties for Vistagen Therapeutics Investors

TIPRANKS
·
Feb 14

VistaGen Therapeutics Faces Investor Class Action Over Failed Drug Trial

Reuters
·
Feb 14

Stifel Nicolaus Reaffirms Their Hold Rating on VistaGen Therapeutics (VTGN)

TIPRANKS
·
Feb 13

VistaGen fiscal Q3 net loss widens to $18.9 mln

Reuters
·
Feb 13

VistaGen Therapeutics Q3 EPS $(0.45) Misses $(0.44) Estimate, Sales $303.000K Miss $366.000K Estimate

Benzinga
·
Feb 13

BRIEF-VistaGen Q3 EPS USD -0.45

Reuters
·
Feb 13

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Feb 13

Nasdaq Warns VistaGen Therapeutics Over Minimum Bid Price Compliance

Reuters
·
Feb 07

VistaGen Therapeutics Inc. to Report Third Quarter Results and Host Corporate Update Call

Reuters
·
Feb 04

Press Release: Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Dow Jones
·
Feb 04

Vistagen Therapeutics (VTGN) Faces Securities Litigation Following 80% Stock Collapse [January 2026]

TIPRANKS
·
Jan 29

VistaGen Therapeutics Reports Phase 3 Fasedienol Trial Fails to Meet Primary Endpoint in Social Anxiety Disorder

Reuters
·
Dec 23, 2025

Vistagen Therapeutics Inc : William Blair Cuts to Market Perform Rating

THOMSON REUTERS
·
Dec 18, 2025

Vistagen Therapeutics Inc : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS
·
Dec 18, 2025

Vistagen Therapeutics Cut to Hold From Buy by Jefferies

Dow Jones
·
Dec 18, 2025

Sector Update: Health Care Stocks Softer Wednesday Afternoon

MT Newswires Live
·
Dec 18, 2025

Vistagen Therapeutics Shares Tumble in Premarket as Anxiety Drug Test Miss Targets

Dow Jones
·
Dec 17, 2025

BRIEF-Vistagen Announces Topline Results From Palisade-3 Phase 3 Study

Reuters
·
Dec 17, 2025

VistaGen Therapeutics Reports Phase 3 Trial of Fasedienol for Social Anxiety Disorder Fails to Meet Primary Endpoint

Reuters
·
Dec 17, 2025

Vistagen Announces Topline Results From Palisade-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Dec 17, 2025